Skip to main content
NCBI home page
Gut logoLink to Gut
. 1995 Sep;37(3):301–304. doi: 10.1136/gut.37.3.301

The ursodeoxycholic acid story in primary biliary cirrhosis.

A G Lim 1, R P Jazrawi 1, T C Northfield 1
PMCID: PMC1382805  PMID: 7590420

Full text

PDF
301

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D. H., Hubscher S. G., Shaw J., Johnson G. D., Babbs C., Rothlein R., Neuberger J. M. Increased expression of intercellular adhesion molecule 1 on bile ducts in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology. 1991 Sep;14(3):426–431. [PubMed] [Google Scholar]
  2. Adams D. H., Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet. 1994 Apr 2;343(8901):831–836. doi: 10.1016/s0140-6736(94)92029-x. [DOI] [PubMed] [Google Scholar]
  3. Bassi C., Falconi M., Pederzoli P. Role of somatostatin and somatostatin analogues in the treatment of gastrointestinal diseases: prevention of complications after pancreatic surgery. Gut. 1994;35(3 Suppl):S20–S22. doi: 10.1136/gut.35.3_suppl.s20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Batta A. K., Arora R., Salen G., Tint G. S., Eskreis D., Katz S. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment. J Lipid Res. 1989 Dec;30(12):1953–1962. [PubMed] [Google Scholar]
  5. Beuers U., Spengler U., Zwiebel F. M., Pauletzki J., Fischer S., Paumgartner G. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology. 1992 Apr;15(4):603–608. doi: 10.1002/hep.1840150409. [DOI] [PubMed] [Google Scholar]
  6. Calmus Y., Arvieux C., Gane P., Boucher E., Nordlinger B., Rouger P., Poupon R. Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology. 1992 Apr;102(4 Pt 1):1371–1377. [PubMed] [Google Scholar]
  7. Calmus Y., Gane P., Rouger P., Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology. 1990 Jan;11(1):12–15. doi: 10.1002/hep.1840110104. [DOI] [PubMed] [Google Scholar]
  8. Calmus Y., Guechot J., Podevin P., Bonnefis M. T., Giboudeau J., Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology. 1992 Sep;16(3):719–723. doi: 10.1002/hep.1840160317. [DOI] [PubMed] [Google Scholar]
  9. Calmus Y., Weill B., Ozier Y., Chéreau C., Houssin D., Poupon R. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology. 1992 Aug;103(2):617–621. doi: 10.1016/0016-5085(92)90855-s. [DOI] [PubMed] [Google Scholar]
  10. Cappell M. S. Hepatobiliary manifestations of the acquired immune deficiency syndrome. Am J Gastroenterol. 1991 Jan;86(1):1–15. [PubMed] [Google Scholar]
  11. Crosignani A., Podda M., Battezzati P. M., Bertolini E., Zuin M., Watson D., Setchell K. D. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology. 1991 Dec;14(6):1000–1007. [PubMed] [Google Scholar]
  12. Dickson E. R., Grambsch P. M., Fleming T. R., Fisher L. D., Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989 Jul;10(1):1–7. doi: 10.1002/hep.1840100102. [DOI] [PubMed] [Google Scholar]
  13. Dumont M., Erlinger S., Uchman S. Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat: possible role of bicarbonate transport. Gastroenterology. 1980 Jul;79(1):82–89. [PubMed] [Google Scholar]
  14. Erlinger S. Hypercholeretic bile acids: a clue to the mechanism? Hepatology. 1990 May;11(5):888–890. doi: 10.1002/hep.1840110527. [DOI] [PubMed] [Google Scholar]
  15. Floreani A., Zappalà F., Mazzetto M., Naccarato R., Plebani M., Chiaramonte M. Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease. Dig Dis Sci. 1994 Jan;39(1):9–14. doi: 10.1007/BF02090053. [DOI] [PubMed] [Google Scholar]
  16. Galle P. R., Theilmann L., Raedsch R., Otto G., Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology. 1990 Sep;12(3 Pt 1):486–491. doi: 10.1002/hep.1840120307. [DOI] [PubMed] [Google Scholar]
  17. Güldütuna S., Zimmer G., Imhof M., Bhatti S., You T., Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]. Gastroenterology. 1993 Jun;104(6):1736–1744. doi: 10.1016/0016-5085(93)90653-t. [DOI] [PubMed] [Google Scholar]
  18. Heathcote E. J., Cauch-Dudek K., Walker V., Bailey R. J., Blendis L. M., Ghent C. N., Michieletti P., Minuk G. Y., Pappas S. C., Scully L. J. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994 May;19(5):1149–1156. [PubMed] [Google Scholar]
  19. Heuman D. M., Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology. 1994 May;106(5):1333–1341. doi: 10.1016/0016-5085(94)90027-2. [DOI] [PubMed] [Google Scholar]
  20. Heuman D. M. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology. 1993 Jun;104(6):1865–1870. doi: 10.1016/0016-5085(93)90672-y. [DOI] [PubMed] [Google Scholar]
  21. Heuman D. M., Pandak W. M., Hylemon P. B., Vlahcevic Z. R. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology. 1991 Nov;14(5):920–926. doi: 10.1002/hep.1840140527. [DOI] [PubMed] [Google Scholar]
  22. Hofmann A. F., Popper H. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet. 1987 Aug 15;2(8555):398–399. doi: 10.1016/s0140-6736(87)92421-4. [DOI] [PubMed] [Google Scholar]
  23. Jazrawi R. P., de Caestecker J. S., Goggin P. M., Britten A. J., Joseph A. E., Maxwell J. D., Northfield T. C. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology. 1994 Jan;106(1):134–142. doi: 10.1016/s0016-5085(94)94899-2. [DOI] [PubMed] [Google Scholar]
  24. Kaplan M. M. Primary biliary cirrhosis--a first step in prolonging survival. N Engl J Med. 1994 May 12;330(19):1386–1387. doi: 10.1056/NEJM199405123301912. [DOI] [PubMed] [Google Scholar]
  25. Kitani K., Ohta M., Kanai S. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat. Am J Physiol. 1985 Apr;248(4 Pt 1):G407–G417. doi: 10.1152/ajpgi.1985.248.4.G407. [DOI] [PubMed] [Google Scholar]
  26. Krähenbühl S., Talos C., Fischer S., Reichen J. Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria. Hepatology. 1994 Feb;19(2):471–479. doi: 10.1002/hep.1840190228. [DOI] [PubMed] [Google Scholar]
  27. Kürktschiev D., Subat S., Adler D., Schentke K. U. Immunomodulating effect of ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. J Hepatol. 1993 Jul;18(3):373–377. doi: 10.1016/s0168-8278(05)80284-3. [DOI] [PubMed] [Google Scholar]
  28. La Villa G., Romanelli R. G., Casini Raggi V., Tosti-Guerra C., De Feo M. L., Marra F., Laffi G., Gentilini P. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology. 1992 Jul;16(1):156–161. doi: 10.1002/hep.1840160126. [DOI] [PubMed] [Google Scholar]
  29. Lacaille F., Paradis K. The immunosuppressive effect of ursodeoxycholic acid: a comparative in vitro study on human peripheral blood mononuclear cells. Hepatology. 1993 Jul;18(1):165–172. [PubMed] [Google Scholar]
  30. Leuschner U., Leuschner M., Sieratzki J., Kurtz W., Hübner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci. 1985 Jul;30(7):642–649. doi: 10.1007/BF01308413. [DOI] [PubMed] [Google Scholar]
  31. Lim A. G., Jazrawi R. P., Ahmed H. A., Levy J. H., Zuin M., Douds A. C., Maxwell J. D., Northfield T. C. Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: relationship with disease stage, immune activity and cholestasis. Hepatology. 1994 Oct;20(4 Pt 1):882–888. doi: 10.1002/hep.1840200416. [DOI] [PubMed] [Google Scholar]
  32. Lim A. G., Jazrawi R. P., Levy J. H., Petroni M. L., Douds A. C., Maxwell J. D., Northfield T. C. Soluble E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in primary biliary cirrhosis. J Hepatol. 1995 Apr;22(4):416–422. doi: 10.1016/0168-8278(95)80104-9. [DOI] [PubMed] [Google Scholar]
  33. Lindor K. D., Dickson E. R., Baldus W. P., Jorgensen R. A., Ludwig J., Murtaugh P. A., Harrison J. M., Wiesner R. H., Anderson M. L., Lange S. M. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994 May;106(5):1284–1290. doi: 10.1016/0016-5085(94)90021-3. [DOI] [PubMed] [Google Scholar]
  34. Lotterer E., Stiehl A., Raedsch R., Foelsch U. R., Bircher J. Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III. J Hepatol. 1990 May;10(3):284–290. doi: 10.1016/0168-8278(90)90134-d. [DOI] [PubMed] [Google Scholar]
  35. Ludwig J., Dickson E. R., McDonald G. S. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978 Aug 22;379(2):103–112. doi: 10.1007/BF00432479. [DOI] [PubMed] [Google Scholar]
  36. Marteau P., Chazouilléres O., Myara A., Jian R., Rambaud J. C., Poupon R. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology. 1990 Nov;12(5):1206–1208. doi: 10.1002/hep.1840120521. [DOI] [PubMed] [Google Scholar]
  37. Mazzella G., Parini P., Bazzoli F., Villanova N., Festi D., Aldini R., Roda A., Cipolla A., Polimeni C., Tonelli D. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig Dis Sci. 1993 May;38(5):896–902. doi: 10.1007/BF01295917. [DOI] [PubMed] [Google Scholar]
  38. Poupon R. E., Chrétien Y., Poupon R., Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology. 1993 Apr;17(4):599–604. doi: 10.1002/hep.1840170412. [DOI] [PubMed] [Google Scholar]
  39. Poupon R. E., Poupon R., Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med. 1994 May 12;330(19):1342–1347. doi: 10.1056/NEJM199405123301903. [DOI] [PubMed] [Google Scholar]
  40. Poupon R., Chrétien Y., Poupon R. E., Ballet F., Calmus Y., Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet. 1987 Apr 11;1(8537):834–836. doi: 10.1016/s0140-6736(87)91610-2. [DOI] [PubMed] [Google Scholar]
  41. Roep B. O., Heidenthal E., de Vries R. R., Kolb H., Martin S. Soluble forms of intercellular adhesion molecule-1 in insulin-dependent diabetes mellitus. Lancet. 1994 Jun 25;343(8913):1590–1593. doi: 10.1016/s0140-6736(94)93055-4. [DOI] [PubMed] [Google Scholar]
  42. Shapiro J. M., Smith H., Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut. 1979 Feb;20(2):137–140. doi: 10.1136/gut.20.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Stiehl A., Raedsch R., Rudolph G. Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids. Gastroenterology. 1990 Feb;98(2):424–428. doi: 10.1016/0016-5085(90)90834-n. [DOI] [PubMed] [Google Scholar]
  44. Stiehl A., Rudolph G., Raedsch R., Möller B., Hopf U., Lotterer E., Bircher J., Fölsch U., Klaus J., Endele R. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology. 1990 Sep;12(3 Pt 1):492–497. doi: 10.1002/hep.1840120308. [DOI] [PubMed] [Google Scholar]
  45. Tsuneyama K., Van de Water J., Leung P. S., Cha S., Nakanuma Y., Kaplan M., De Lellis R., Coppel R., Ansari A., Gershwin M. E. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression. Hepatology. 1995 Apr;21(4):1031–1037. [PubMed] [Google Scholar]
  46. Van de Water J., Turchany J., Leung P. S., Lake J., Munoz S., Surh C. D., Coppel R., Ansari A., Nakanuma Y., Gershwin M. E. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest. 1993 Jun;91(6):2653–2664. doi: 10.1172/JCI116504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wolfhagen F. H., van Buuren H. R., Schalm S. W. Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis. Neth J Med. 1994 Mar;44(3):84–90. [PubMed] [Google Scholar]
  48. Yoshikawa M., Tsujii T., Matsumura K., Yamao J., Matsumura Y., Kubo R., Fukui H., Ishizaka S. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology. 1992 Aug;16(2):358–364. doi: 10.1002/hep.1840160213. [DOI] [PubMed] [Google Scholar]
  49. de Caestecker J. S., Jazrawi R. P., Petroni M. L., Northfield T. C. Ursodeoxycholic acid in chronic liver disease. Gut. 1991 Sep;32(9):1061–1065. doi: 10.1136/gut.32.9.1061. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES